As part of the IP Osgoode Speaks Series, Dr. Siva Thambisetty, an associate professor of law at the London School of Economics, visited Osgoode Hall Law School to speak on…
Category: Patent Practice
Utility Emphasis Lacking in the Examination of Aggregations
The distinction between combinations and aggregations is a well-accepted principle of patent law. A combination is an assemblage of known elements whose combined use leads to a result that is…
The View Ahead for Software Patent Applications: USPTO Releases Update to Guidance on Patent Subject Matter Eligibility
This article is cross-posted with permission from Bereskin & Parr. The United States Patent and Trademarks Office (USPTO) has released an updated set of Eligibility Examination Guidelines to provide guidance…
Patent Strategies in Your First Few Years of a New Business
Introduction A new business that plans to bring a new and innovative product or service to market ought to address patents right from the first draft of their business plan.…
An Unexpected Infringement: There and Back Again
On March 16, 2015, Justice Barnes held that AstraZeneca’s Patent No 1,292,693 (“’693 Patent”), a formulation patent for omeprazole, was valid and infringed by Apotex (2015 FC 322). This decision…
in Feature Post, IP Reform, Patent Practice, Patentability, Patents, Pharmaceutical Drugs0by Editor
1256
China’s Bitter Medicine for Gilead: SIPO Cancels Viread Patent
Last August, China’s State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences‘ flagship drug Viread (as was reported by IPR Daily and a number of other news sources). This…